Potassium voltage-gated channel subfamily A member 4 (N-terminal deletion mutant) (Kv1.4ΔN)

The Kv1.4ΔN voltage-gated potassium channel is an engineered variant of the Potassium voltage-gated channel subfamily A member 4 (KCNA4), characterized by the deletion of its N-terminal inactivation domain [1]. In its native state, Kv1.4 is a Shaker-related channel that mediates a rapidly inactivating "A-type" potassium current, which is essential for controlling the timing and frequency of action potentials in the central nervous system and the heart [1, 2]. The ΔN truncation removes the "ball-and-chain" mechanism responsible for this rapid N-type inactivation, creating a channel that remains open longer or inactivates much more slowly via C-type mechanisms [2, 3]. This modification makes the Kv1.4ΔN construct a vital tool in pharmacological research, as it allows for the precise study of drug-binding kinetics and pore-blocking mechanisms without the confounding influence of fast gating [3, 4]. While the wild-type KCNA4 protein is a therapeutic target of interest for conditions such as cardiac arrhythmias and epilepsy, the ΔN version is specifically a laboratory construct used to facilitate drug discovery and electrophysiological characterization [4, 5]. Common drugs that interact with this channel include antiarrhythmics like flecainide and quinidine, as well as certain antidepressants and calcium channel blockers that exhibit off-target effects on potassium conductance [5, 6].

Other names

KCNA4Voltage-gated potassium channel subunit Kv1.4Shaker-related potassium channel member 4HK1PCN2

Pore blockade of the alpha subunit, inhibiting potassium efflux and prolonging action potential duration.